IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC

2021499 citationsJournal Articlehybrid Open Access

Authors

Mark A. Socinski · Florida Hospital Cancer Institute

Makoto Nishio · Japanese Foundation For Cancer Research

Robert M. Jotte · Texas Oncology

Federico Cappuzzo · Instituto Nazionale Tumori Regina Elena

Francesco Orlandi · Instituto Nacional del Tórax

Daniil Stroyakovskiy · Moscow City Oncology Hospital №62

Naoyuki Nogami

Abstract

At the final IMpower150 OS analysis, ACP had numerical, but not statistically significant, OS improvement versus BCP. Updated data with an additional 20 months of follow-up revealed continued OS improvement with ABCP versus BCP in all patients.

Topics & Keywords

Cancer Immunotherapy and Biomarkers Colorectal Cancer Treatments and Studies Lung Cancer Treatments and Mutations

Publication Details

Published in: Journal of Thoracic Oncology

Volume 16, Issue 11, pp. 1909-1924

DOI: 10.1016/j.jtho.2021.07.009

Field-Weighted Citation Impact: 30.69

Command Palette

IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC

Authors

Abstract

Topics & Keywords

Publication Details